142.99 0.00 (0.00%)
After hours: 5:58PM EST
|Bid||142.80 x 900|
|Ask||142.81 x 800|
|Day's Range||138.96 - 143.03|
|52 Week Range||94.59 - 147.33|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||42.42|
|Earnings Date||Jan 27, 2020 - Jan 31, 2020|
|Forward Dividend & Yield||0.68 (0.50%)|
|1y Target Est||152.71|
The three major U.S. stock market indexes posted gains despite slumping industrial-production and retail-sales numbers, which painted a mixed picture of U.S. consumer demand.
WASHINGTON, Nov. 15, 2019 /PRNewswire/ -- Danaher Corporation (DHR) announced today that it will commence an exchange offer related to the split-off of its remaining interest in Envista Holdings Corporation (NYSE:NVST). Envista completed its initial public offering (IPO) in September 2019, with Danaher retaining an 80.6 percent ownership interest in Envista. In the exchange offer, Danaher stockholders have the option to exchange all, some or none of their shares of Danaher common stock for shares of Envista common stock owned by Danaher, subject to the terms of the offer.
BREA, Calif., Nov. 15, 2019 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) announced it intends to file a Form S-4/S-1 Registration Statement today with the Securities and Exchange Commission (SEC) in connection with Danaher's (DHR) proposed offer to exchange shares of Envista common stock it owns for shares of Danaher common stock. In the offer, Danaher shareholders will have the opportunity to exchange some or all their shares of Danaher common stock for shares of Envista common stock. The exchange offer is anticipated to be tax-free for participating Danaher shareholders in the United States, except with respect to cash received in lieu of fractional shares.
WASHINGTON, Nov. 13, 2019 /PRNewswire/ -- Danaher Corporation (DHR) announced today that it has appointed Jessica L. Mega, MD, MPH and Pardis C. Sabeti, MD, D.Phil to its Board of Directors. Dr. Mega is currently Chief Medical and Scientific Officer of Verily Life Sciences LLC, an Alphabet, Inc. company, where she has served since March 2015. Prior to joining Verily, she served as Cardiologist and Senior Investigator at Brigham & Women's. Dr. Mega has also served as a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, where she helped lead international trials evaluating novel cardiovascular therapies and directed the genetics program.
Investors focused on climate change and sustainability often want “water plays,” or stocks that benefit from the rising scarcity of water.
Investors pushed shares of GE up nearly 12% after better than expected third quarter results, but at least one analyst thinks that rally was unjustified.
(Bloomberg Opinion) -- General Electric Co.’s path to recovery is a long one, but the company no longer seems lost in the woods. In releasing its third-quarter results on Wednesday, GE also raised its guidance for 2019 free cash flow and now anticipates its industrial businesses could bring in as much as $2 billion this year. That’s a $4 billion swing from GE’s worst-case scenario in its initial March forecast. There’s a fine line between setting a low bar and sandbagging the numbers, but GE’s rosier outlook is supported by signs of stabilization in its beleaguered power unit and there being less of a drag than anticipated from the transition of a supply-chain financing program to a third party. The aviation business was also able to largely offset the negative impact of the continued grounding of Boeing Co.’s 737 Max. Those were key worry points that ended up not being as worrisome.It wasn’t a perfect quarter and there are some notable footnotes to that guidance increase. Still, a lack of nasty surprises and minimal signs to date of macroeconomic weakness in GE’s aviation and health-care businesses make this a victory for CEO Larry Culp. A flurry of deleveraging activities in the last two months had raised concerns that GE was trying to give itself some good news to talk about if the actual quarterly numbers were disappointments, particularly amid growing concerns that a manufacturing slowdown was deepening. That fear appears unfounded, at least as far as the last three months are concerned for GE’s businesses.Shares of GE rallied as much as 14% on the report, essentially erasing a slide since its last earnings update in July that in part reflected concerns over the impact of slumping interest rates. The decline in rates forced GE to reassess its expectations for the returns it will get on assets supporting the company’s long-term-care insurance business. While this contributed to a $1 billion pre-tax charge in the latest quarter as the company bolstered its GAAP reserves, it’s better than the “ somewhere south” of $1.5 billion adjustment – before other offsets – that Culp had flagged in September. And it’s certainly nowhere in the ballpark of what’s implied in the $29 billion reserve shortfall Bernie Madoff whistle-blower Harry Markopolos claimed existed.Operating profit for the power segment turned negative again after a few quarters of positive numbers. But margins did improve in that business – to negative 3.7% from negative 14.8% a year earlier – which GE says reflects better pricing discipline. The company now expects the cash burn at the power unit to be no worse than the $2.3 billion outflow last year (adjusted for a reorganization of that business), versus an initial prediction of a substantial year-over-year weakening. The health-care division saw a nice lift in profit margins and a 5% jump in sales, even as its imaging business struggled in China and some larger U.S> projects got pushed out. And aviation rebounded from an uncharacteristically weak second quarter. These are all positive data points that speak to Culp’s push for operational improvements.What hasn’t changed is that even at $2 billion, GE’s free cash flow will be very weak this year. The current forecast compares to $4.5 billion last year and $5.6 billion in 2017. While a stronger starting point in 2019 certainly helps, GE will have to overcome a number of challenges to get back to even those depressed levels. Already, GE will lose about $1 billion in free cash flow in 2020 from the sale of its biopharmaceutical business to Danaher Corp., per analysts’ estimates. Despite an improved performance in 2019, there’s no update at this time for GE’s expectation for the power unit to continue burning cash next year. And GE has to keep spending on restructuring. It again lowered its estimate for the cost of these cutbacks this year (which was a boon to its free-cash-flow outlook) in part because of the “timing” of politically fraught conversations in Europe over facilities and employees absorbed as part of its disastrous acquisition of Alstom SA’s power business. Keeping economic headwinds at bay will also be key. Meanwhile, GE will get lower contributions from Baker Hughes as it continues to wind down its stake; a divestiture in September pushed that holding below 50%, forcing the company to take an $8.7 billion pre-tax charge in the quarter.Culp is doing what he needs to do to stop the bleeding at GE. Now the conversation shifts to what kind of company this is going to look like when he’s done and how far this turnaround can go. To contact the author of this story: Brooke Sutherland at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Brooke Sutherland is a Bloomberg Opinion columnist covering deals and industrial companies. She previously wrote an M&A column for Bloomberg News.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
General Electric's (GE) third-quarter 2019 earnings rise year over year on improved margin profile. It raises the free cash flow (Industrial) view for 2019.
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured notes of DH Europe Finance II S.a r.l., an indirect and wholly owned subsidiary of Danaher Corporation ("Danaher"). Danaher will fully and unconditionally guarantee the new notes. Proceeds from the new USD notes will be used in conjunction with additional debt, equity and existing cash on hand to fund the roughly $21 billion acquisition of GE's biologics business ("GE Biopharma"), which will be rebranded as "Cytiva".
WASHINGTON , Oct. 29, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that its wholly owned subsidiary, DH Europe Finance II S.à r.l. ("Danaher International ...
WASHINGTON , Oct. 28, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr. , will be presenting at the Baird Global Industrial ...
Danaher's (DHR) third-quarter 2019 earnings benefit from organic sales growth, acquisitions and DBS initiatives. It lowers 2019 projection, accounting for the Envista transaction.
Shares of Danaher Corp. fell 1.6% in premarket trading Thursday, after the medical technology and products company beat profit and revenue expectations, but provided a downbeat earnings outlook. Net income fell to $648.4 million or 89 cents a share, from $663.7 million, or 93 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew 5.5% to $1.16 to top the FactSet consensus of $1.15. Sales increased to $5.04 billion from $4.85 billion, above the FactSet consensus of $5.02 billion. The company expects fourth-quarter adjusted EPS of $1.32 to $1.35, below the FactSet consensus of $1.37, and trimmed its 2019 guidance range to $4.74 to $4.77, after raising it to $4.75 to $4.80 in July. The stock has run up 34.3% year to date through Wednesday, while the SPDR Health Care Select Sector ETF has gained 6.8% and the S&P 500 has rallied 19.9%.
Danaher (DHR) delivered earnings and revenue surprises of 0.87% and -0.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
WASHINGTON , Oct. 24, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2019. For the quarter ended September 27, 2019 , net earnings attributable to Danaher ...
The shares are a bit lower after the life-sciences company beat Wall Street's third-quarter-earnings estimates but offered disappointing guidance.